Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Inventory (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Inventory for 6 consecutive years, with $14.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Inventory rose 31.0% to $14.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.0 million, a 31.0% increase, with the full-year FY2025 number at $14.0 million, up 31.0% from a year prior.
  • Inventory was $14.0 million for Q4 2025 at GeneDx Holdings, up from $10.6 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $44.2 million in Q3 2022 to a low of $8.8 million in Q4 2023.
  • A 5-year average of $19.8 million and a median of $12.5 million in 2023 define the central range for Inventory.
  • Peak YoY movement for Inventory: surged 42.82% in 2022, then tumbled 78.84% in 2023.
  • GeneDx Holdings' Inventory stood at $33.5 million in 2021, then plummeted by 59.16% to $13.7 million in 2022, then plummeted by 35.77% to $8.8 million in 2023, then increased by 21.34% to $10.6 million in 2024, then surged by 31.0% to $14.0 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Inventory are $14.0 million (Q4 2025), $10.6 million (Q3 2025), and $11.9 million (Q2 2025).